Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 12/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 12/20 | 1.00 |
| ▸ | BRD4 | O60885 | 6/20 | 0.63 |
| ▸ | EGFR | P00533 | 1/20 | 0.62 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.62 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26395502 | 1.00 | PDGFRB (1.00) | PDGFRBPDGFRABRD4EGFRFGFR1 | |
| SCHEMBL26395575 | 0.93 | PDGFRB (1.00) | PDGFRBPDGFRAEGFRALK | |
| SCHEMBL29793855 | 0.93 | PDGFRB (1.00) | PDGFRBPDGFRAEGFRALK | |
| SCHEMBL24625496 | 0.92 | PDGFRA (1.00) | PDGFRBPDGFRABRD4EGFRFGFR1 | |
| SCHEMBL29793778 | 0.92 | PDGFRA (1.00) | PDGFRBPDGFRABRD4EGFRFGFR1 | |
| SCHEMBL24625523 | 0.87 | PDGFRB (0.83) | PDGFRBPDGFRABRD4EGFRFGFR1 | |
| SCHEMBL29793840 | 0.85 | PDGFRB (1.00) | PDGFRBPDGFRABRD4EGFRFGFR1 | |
| SCHEMBL26395520 | 0.85 | PDGFRB (1.00) | PDGFRBPDGFRABRD4EGFRFGFR1 | |
| SCHEMBL26394706 | 0.84 | EGFR (0.77) | PDGFRBPDGFRABRD4EGFRFGFR1 | |
| SCHEMBL24625494 | 0.81 | PDGFRB (1.00) | PDGFRBPDGFRABRD4EGFRFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858914-B2 | Pyrimidine small-molecule compound and application thereof | WENZHOU MEDICAL UNIVERSITY (CN) | 2024-01-02 | — | — | US | disclosed |
| US-20230312529-A1 | PYRIMIDINE SMALL-MOLECULE COMPOUND AND APPLICATION THEREOF | WENZHOU MEDICAL UNIVERSITY (CN) | 2023-10-05 | — | — | US | disclosed |
| CN-112778282-B | Pyrimidine micromolecule compound and application thereof | 温州医科大学 | 2022-07-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312529-A1 | PYRIMIDINE SMALL-MOLECULE COMPOUND AND APPLICATION THEREOF | PDGFRB, PDGFRA, RB1 | PDGFRB 1/4885PDGFRA 2/4885BRD4 1398/4885 |
| US-11858914-B2 | Pyrimidine small-molecule compound and application thereof | PDGFRB, PDGFRA, RB1 | PDGFRB 1/4885PDGFRA 2/4885BRD4 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.